Clinical Cancer Research AACR Conference on Cancer Prevention Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theodorescu, D.
Right arrow Articles by Frierson, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theodorescu, D.
Right arrow Articles by Frierson, H. F., Jr.
Clinical Cancer Research Vol. 10, 3800-3806, June 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer

Dan Theodorescu1, L. M. Sapinoso2, M. R. Conaway3, G. Oxford1, G. M. Hampton2 and H. F. Frierson, Jr.4

1 Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia; 2 Genomics Institute of the Novartis Research Foundation, San Diego, California; and Departments of 3 Health Evaluation Sciences (Biostatistics) and 4 Pathology, University of Virginia Health Sciences Center, Charlottesville, Virginia

Purpose: RhoGDI2 was recently shown to be a metastasis suppressor gene in models of bladder cancer. We sought to further understand its importance in human cancer by determining the level of its expression and the distribution of its encoded protein in normal human tissues and cell lines and to evaluate whether its protein expression is a determinant of human bladder cancer progression.

Experimental Design: RhoGDI2 mRNA and protein expression was evaluated in cell lines and human tissues using Affymetrix and tissue microarrays, respectively. Tissue microarrays represented most human normal adult tissues and material from 51 patients that had undergone radical cystectomy for bladder cancer. In these 51 patients, the {chi}2 test was used to test for associations between RhoGDI2 and stage, grade of urothelial carcinoma, histological type, and disease-specific survival status. Cox proportional hazards regression analyses were used to estimate the effect of RhoGDI2 expression level on time to development of metastatic disease and disease-specific survival time, adjusting for grade, stage, and histological type.

Results: In normal tissues, there was strong RhoGDI2 protein expression in WBCs, endothelial cells, and transitional epithelium. RhoGDI2 mRNA expression was inversely related to the invasive and metastatic phenotype in human bladder cancer cell lines. In patients with bladder cancer, univariate analysis indicated that reduced tumor RhoGDI2 protein expression was associated with a lower actuarial 5-year disease-free and disease-specific survival (P = 0.01). In addition, patients with tumors that had low or absent RhoGDI2 had a shorter time to disease-specific death (P <= 0.01). When tumor grade, stage, histological type, and RhoGDI2 staining level were examined using multivariate analysis, RhoGDI2 expression was found to be an independent predictive factor for disease-specific death (P = 0.03).

Conclusions: These results suggest that RhoGDI2 is an independent predictor of prognosis for patients with bladder cancer and provide clinical evidence in support of its involvement in cancer metastasis.




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. Schunke, P. Span, H. Ronneburg, A. Dittmer, M. Vetter, H.-J. Holzhausen, E. Kantelhardt, S. Krenkel, V. Muller, F. C.G.J. Sweep, et al.
Cyclooxygenase-2 Is a Target Gene of Rho GDP Dissociation Inhibitor {beta} in Breast Cancer Cells
Cancer Res., November 15, 2007; 67(22): 10694 - 10702.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu
Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application.
Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889.
[Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhang and B. Zhang
D4-GDI, a Rho GTPase Regulator, Promotes Breast Cancer Cell Invasiveness
Cancer Res., June 1, 2006; 66(11): 5592 - 5598.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. C. Smith, G. Oxford, Z. Wu, M. D. Nitz, M. Conaway, H. F. Frierson, G. Hampton, and D. Theodorescu
The Metastasis-Associated Gene CD24 Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human Cancer
Cancer Res., February 15, 2006; 66(4): 1917 - 1922.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Oxford, C. R. Owens, B. J. Titus, T. L. Foreman, M. C. Herlevsen, S. C. Smith, and D. Theodorescu
RalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Cancer Res., August 15, 2005; 65(16): 7111 - 7120.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu
Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2
Cancer Res., August 15, 2005; 65(16): 7320 - 7327.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.